GlucoTrack, Inc. (GCTK)
| Market Cap | 1.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.39M |
| Shares Out | 1.94M |
| EPS (ttm) | -31.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 860,471 |
| Open | 0.720 |
| Previous Close | 0.723 |
| Day's Range | 0.675 - 0.837 |
| 52-Week Range | 0.619 - 15.900 |
| Beta | 0.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About GCTK
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent... [Read more]
Financial Performance
Financial StatementsNews
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
RUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercializa...
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 Experience From Brazilian an...
GlucoTrack Transcript: EGM 2026
Three key proposals were presented: share issuances to an investor, warrant exercise approval, and auditor ratification. All proposals received the required stockholder approval, with final results to be filed with the SEC.
Glucotrack to Present at LSI USA '26 Medtech Innovation Summit
RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization...
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization ...
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (the “Company”), a medical technology company focused on the design, development, and commercialization of novel tech...
Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expe...
GlucoTrack Transcript: AGM 2025
A reconvened special meeting aimed to approve a major stock issuance but was permanently adjourned due to lack of quorum, with only 17.6% of eligible votes represented.
Glucotrack, Inc. Encourages Shareholders to Vote
The Special Meeting of Shareholders reconvenes on November 7, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- G...
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization ...
Glucotrack, Inc. Reminds Shareholders to Vote
The Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Glucotr...
GlucoTrack Transcript: Q3 Investor Summit Group Virtual Conference 2025
A fully implantable, three-year continuous blood glucose monitor is being developed, targeting a 3 million patient U.S. market segment underserved by current wearables. Clinical trials are underway in Australia and planned for the U.S., with commercial approval aimed for late 2028.
Glucotrack to Participate in the Q3 Virtual Investor Summit
RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercializa...
Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
Experienced cardiac electrophysiologist joins Glucotrack's growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestones Experienced cardiac electrophy...
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
Company to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot study Company to present endocrinologist perspectives on implantable CBGM technology as it...
Glucotrack Announces Repurchase of Series A Warrants
RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people...
Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?
Glucotrack Inc. GCTK stock traded higher on Wednesday, with a session volume of 15.91 million compared to the average of 81.7K, according to data from Benzinga Pro.
Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions
RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technolog...
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “C...
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glu...
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Exper...
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology Patients get a seat at the table in development of long-term implantable continu...
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025